Correction: Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer

Correction: Biomark Res 7, 16 (2019)

https://doi.org/10.1186/s40364-019-0168-9

The original article [1] contains the following errors:

• 1) The ordinate scale is displayed incorrectly in Fig. 2D-F.

• 2) Fig. 3E was duplicated over Fig. 3F.

• 3) Table 3 contained data in the ‘HR’, ‘95% CI’, and ‘P-value’ columns of the ‘Adjuvant chemotherapy’ and ‘Non-chemotherapy’ rows that should have been deleted.

Fig. 2

Transcriptional levels of PRDXs in various BrCa subclasses. The transcriptional level of PRDXs in BrCa patients with different subclasses, PRDXs mRNA was significantly downregulated (PRDX3) or upregulated (other PRDXs) in HER2-positive and triple-negative BrCa tissues compared with luminal BrCa tissues. a PRDX1. b PRDX2. c PRDX3. d PRDX4. e PRDX5. f PRDX6

Fig. 3

Correlation between the genetic alterations of PRDXs and mRNA levels in BrCa tissues. a Oncoprint in cBioPortal database exhibited the proportion and distribution of specimens with genetic alterations in PRDXs. The Figure was cropped on the right to exclude specimens without any alterations. b-g Copy gain (gain and amplification) of PRDXs was associated with notably upregulated PRDXs mRNA levels compared with the copy-neutral (diploid) and copy-loss (shallow deletion and deep deletion) cases. b PRDX1. c PRDX2. d PRDX3. e PRDX4. f PRDX5. g PRDX6

Table 3 Association between prognostic value of PRDXs mRNA expression and various chemotherapies in BrCa

The corrected Fig. 2, Fig. 3, and Table 3 all appear ahead. The authors apologize for this error and state that this does not change the scientific conclusion in any way.